These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

821 related items for PubMed ID: 29370427

  • 1. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C.
    J Natl Cancer Inst; 2017 Dec 01; 109(12):. PubMed ID: 29370427
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y, Yamamoto H, Iwasaki T, Sato M, Jiromaru R, Hongo T, Yasumatsu R, Oda Y.
    Hum Pathol; 2020 Dec 01; 106():82-92. PubMed ID: 32980422
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F, Lambros L, Le Flahec G, Marcorelles P, Uguen A.
    Clin Lung Cancer; 2018 Sep 01; 19(5):e647-e653. PubMed ID: 29801706
    [Abstract] [Full Text] [Related]

  • 4. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F, Rossi G, Cozzolino I, Montella M, Micheli M, Bogina G, Munari E, Brunelli M, Franco R.
    J Clin Pathol; 2020 Feb 01; 73(2):96-101. PubMed ID: 31562206
    [Abstract] [Full Text] [Related]

  • 5. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
    Digumarthy SR, Mendoza DP, Lin JJ, Chen T, Rooney MM, Chin E, Sequist LV, Lennerz JK, Gainor JF, Shaw AT.
    Clin Lung Cancer; 2020 Mar 01; 21(2):153-159.e3. PubMed ID: 31708389
    [Abstract] [Full Text] [Related]

  • 6. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ, Varella-Garcia M.
    Mol Cancer Res; 2014 Jan 01; 12(1):111-8. PubMed ID: 24296758
    [Abstract] [Full Text] [Related]

  • 7. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.
    Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C.
    Ann Oncol; 2018 Jun 01; 29(6):1394-1401. PubMed ID: 29538669
    [Abstract] [Full Text] [Related]

  • 8. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, Kühl H, Stuschke M, Schmid KW, Schuler M.
    J Thorac Oncol; 2017 Jan 01; 12(1):54-64. PubMed ID: 27575422
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
    Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS, Smith R, Somwar R, Rekhtman N, Ladanyi M, Riely GJ, Kris MG.
    Ann Oncol; 2016 Jul 01; 27(7):1286-91. PubMed ID: 27056998
    [Abstract] [Full Text] [Related]

  • 10. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L, Xu M, Jiang X, Sun X.
    Med Sci Monit; 2018 Dec 23; 24():9364-9369. PubMed ID: 30580372
    [Abstract] [Full Text] [Related]

  • 11. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K, Mochizuki M, Kohno M, Shu S, Harada N, Yoshimura Y.
    BMC Cancer; 2019 Apr 03; 19(1):301. PubMed ID: 30943926
    [Abstract] [Full Text] [Related]

  • 12. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
    Clavé S, Rodon N, Pijuan L, Díaz O, Lorenzo M, Rocha P, Taus Á, Blanco R, Bosch-Barrera J, Reguart N, de la Torre N, Oliveras G, Espinet B, Bellosillo B, Puig X, Arriola E, Salido M.
    Clin Lung Cancer; 2019 Jul 03; 20(4):e421-e429. PubMed ID: 30898567
    [Abstract] [Full Text] [Related]

  • 13. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
    Luk PP, Selinger CI, Mahar A, Cooper WA.
    Arch Pathol Lab Med; 2018 Aug 03; 142(8):922-928. PubMed ID: 29902067
    [Abstract] [Full Text] [Related]

  • 14. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A.
    Lung Cancer; 2014 Feb 03; 83(2):168-73. PubMed ID: 24380695
    [Abstract] [Full Text] [Related]

  • 15. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S, Li X, Zhou C.
    Cancer Med; 2019 Jun 03; 8(6):2858-2866. PubMed ID: 31016879
    [Abstract] [Full Text] [Related]

  • 16. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
    Deng H, Liu C, Zhang G, Wang X, Liu Y.
    Pathol Res Pract; 2018 Dec 03; 214(12):2103-2105. PubMed ID: 30327151
    [Abstract] [Full Text] [Related]

  • 17. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
    Yao Y, Peng M, Shen Q, Hu Q, Gong H, Li Q, Zheng Z, Xu B, Li Y, Dong Y.
    Thorac Cancer; 2019 Feb 03; 10(2):193-202. PubMed ID: 30565433
    [Abstract] [Full Text] [Related]

  • 18. CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas.
    Woo JH, Kim TJ, Kim TS, Han J.
    Sci Rep; 2020 Oct 01; 10(1):16251. PubMed ID: 33005033
    [Abstract] [Full Text] [Related]

  • 19. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
    Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke S, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MR, O'Toole SA, Cooper WA.
    Histopathology; 2017 Feb 01; 70(3):402-411. PubMed ID: 27599111
    [Abstract] [Full Text] [Related]

  • 20. Comprehensive analysis of ALK, ROS1 and RET rearrangements in locally advanced rectal cancer.
    Zhou C, Li M, Guo Z, Li K, Zhai X, Xie Y, Yang X, Wu Y, Xiao W, Xu W.
    J Genet; 2020 Feb 01; 99():. PubMed ID: 33168793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.